

9th SA

TB

Conference



WUJKA

**Let's unite towards a
TB-free world!**

Conference Programme



WE EXTEND OUR GRATITUDE TO OUR SPONSORS





Message from the Chair and Co-Chair



**PROF. MOHLOPHENI JACKSON
MARAKALALA**
Conference Chair



DR. NKATEKO MKHONDO
Conference Co-Chair

On behalf of the Scientific Programme Committee, we warmly welcome you to the **9th South African TB Conference**. It is a privilege to bring together this vibrant community of researchers, clinicians, policy makers, advocates, and partners who share a common commitment to ending TB.

TB remains one of the most formidable public health challenges of our time, with Africa continuing to carry the greatest burden. Yet, this reality also places our continent at the heart of the solution. Through scientific innovation, policy reform, community engagement, and unwavering commitment, we have made meaningful progress; but our work is far from complete. Accelerated prevention, improved case finding, and strengthened diagnostic and treatment tools remain urgent priorities, alongside addressing the social and structural drivers of the epidemic.

This conference embraces the full complexity of the TB response. The programme has been thoughtfully designed to foster collaboration and bold thinking across disciplines; with track one focused on Basic, Translational, and Clinical Sciences; track two on Prevention, Vaccines, and Treatment Strategies; track three on Epidemiology, Surveillance, and Health Systems; and track four on Human Rights, Policy, and Lived Experience. Together, these conversations aim to spark innovation, deepen partnerships, and translate knowledge into action.

At a time of global financial constraints affecting public health, we are called not to retreat, but to rise. The theme of the 2026 SA TB Conference, **“Vuka! Let’s unite towards a TB-free world!”** is a rallying cry for resilience, leadership, and collective action. It calls on all of us, government, academia, civil society, funders, and communities to stand together and lead the charge towards a TB-free future. We invite you to engage fully, share boldly, and collaborate openly. May this conference energise our efforts, strengthen our resolve, and inspire renewed commitment to ending TB.

Welcome, and enjoy the conference!



Meet the Experts behind the 9th SA TB Conference 2026!



CONFERENCE CHAIR
Prof. Mohlopheni Jackson
Marakalala



CONFERENCE CO-CHAIR
Dr. Nkateko Mkhondo



TRACK 1 CHAIR
Dr. Shaheed Vally Omar



TRACK 1 CO-CHAIR
Prof. Neil Martinson



TRACK 2 CHAIR
Prof. Kogieleum Naidoo



TRACK 2 CO-CHAIR
Dr. Marian Loveday



TRACK 3 CHAIR
Dr. Limakatso Lebina



TRACK 3 CO-CHAIR
Dr. Priashni Subrayen



TRACK 3 CO-CHAIR
Dr. Mamothe Makgabo



TRACK 4 CHAIR
Dr. Rogerio Phili



TRACK 4 CO-CHAIR
Mr. David Macana

#SATBConference2026



8 June 2026

Plenary Speaker Biographies



MMC Mr Siyabonga Moloji

Mr Siyabonga Moloji is the Municipal Manager of Community services in the City of Ekurhuleni, which includes health care services. Before being MMC, he served in various committees, including GEYODI. He is currently finishing his degree in Public Administration with the University of Johannesburg.



Prof. Kogieleum Naidoo

Deputy Director, CAPRISA

Prof. Kogieleum Naidoo, MBChB, PhD (UKZN), is Deputy Director at CAPRISA and an Honorary Associate Professor at the University of KwaZulu-Natal. Her research on TB-HIV integration has significantly influenced global policies and treatment strategies. Supported by leading international funders, she has authored over 200 peer-reviewed papers and contributed to major global health books. Her work has been recognized with several honours, including election to the African Academy of Sciences (2025), the Royal Society of South Africa (2023), and ASSAf (2022), the EDCTP Outstanding Female Scientist Award (2023), the SAMRC Silver Medal (2024), and the Union Scientific Prize (2013).



Dr. Dennis Falzon

Public Health Specialist and Epidemiologist, World Health Organization

Dr. Dennis Falzon works at the Department for HIV, TB, Hepatitis and Sexually Transmitted Infections of the World Health Organization (WHO) in Geneva, Switzerland. Before joining WHO in 2008, he was a medical epidemiologist at the EuroTB surveillance project in France and earlier worked in public health in state and non-governmental sectors. Dr. Falzon is involved in the development of guidance on TB screening and TB prevention; the integration of digital technologies and innovations in support of the End TB Strategy; country preparedness for new TB vaccines; and evidence gathering and dissemination.



Prof. Grant Theron

Professor, Stellenbosch University

Grant is based in Cape Town, South Africa, where he leads a research group (CLIME) dedicated to pursuing practical and translatable solutions to end TB via Africa-centred excellence in training and research. CLIME's research uses diverse clinical and laboratory facilities and spans diagnostics, transmission, and the microbiome. This work has led to improvements in the standard-of-care for people affected by TB.



8 June 2026

Plenary Speaker Biographies



Dr. Pakishe Aaron Motsoaledi

Minister of Health
National Department of Health
Republic of South Africa

Dr. Aaron Motsoaledi is a South African medical doctor, anti-apartheid activist, and senior African National Congress (ANC) politician. He currently serves as South Africa's Minister of Health, a position he resumed in June 2024.

Education & Early Career

Motsoaledi studied medicine at the University of Natal, where he became involved in student politics and anti-apartheid activism. After qualifying as a doctor, he worked in rural hospitals and clinics in Limpopo.

Key Contributions

Dr. Motsoaledi is especially known for expanding access to antiretroviral (ARV) treatment, leading major national campaigns against HIV/AIDS and TB, driving healthcare reforms in South Africa, and improving immigration systems during his tenure at Home Affairs.



Prof. Mosa Moshabela

Vice-Chancellor and Principal
University of Cape Town

Professor Mosa Moshabela is a Professor of Public Health and Deputy Vice-Chancellor for Research and Innovation at the University of KwaZulu-Natal. He oversees a broad institutional portfolio including research management, ethics and integrity, capacity development, innovation, entrepreneurship, technology transfer, and commercialisation. He is an esteemed clinician-scientist and a member of the Academy of Science of South Africa. His contributions have been recognised with the PHILA Annual Award from PHASA in 2022 for his impact on public health, as well as a Ministerial Special COVID-19 Award for science communication and public engagement during the pandemic.

He serves as Chairperson of the National Research Foundation Governing Board and is a Health Commissioner to the Premier of KwaZulu-Natal. He is a former board member of the SAMRC and previously chaired ASSAf's Standing Committee on Health. His research focuses on implementation science, health systems, HIV, TB, and improving equitable healthcare in resource-limited settings across sub-Saharan Africa. He leads the QuEST Centre in collaboration with Harvard University and contributes to global advisory boards including The Lancet and NASEM initiatives.



Ms. Ntswaki Mosia-Motaung

TB Ambassador, Person with lived experience

In 2009, shortly after moving from the Free State to Pretoria for work, the narrator began experiencing severe TB symptoms, including persistent coughing, night sweats, weight loss, chest pains, fatigue, and loss of appetite. Although initial sputum tests came back negative, a trusted healthcare professional in Bethlehem suspected TB and arranged further tests. X-rays later revealed holes in the lungs, confirming the diagnosis, and treatment with Rifampin was started. During treatment, she developed severe shingles, which was managed with medication and traditional remedies, and successfully completed the full 9-month TB treatment course.

In 2014, after relocating to Johannesburg, TB returned. This time the symptoms included fatigue, coughing, weight loss, and loss of appetite. The illness became so severe that she could not get out of bed, prompting a caring landlord to contact their mother, who took them home for medical care. Sputum tests confirmed TB, and again completed a full 9-month course of treatment without complications. The narrator expresses gratitude for the healthcare professionals who supported them and hopes their story encourages others to screen for TB, start treatment early, complete the treatment course, and speak openly about TB. Their message is clear: TB is curable and manageable, and everyone has a role to play in helping South Africa achieve a TB-free future by 2030.



8 June 2026

Satellite Session

National Department of Health (NDoH), Republic of South Africa

Time: 10:00 – 13:00

Venue: Cape Town International

Opening Plenary Session

Time: 15:00 – 17:30

Venue: OR Tambo

Session Chair: Prof. Jackson

Mohlopheni Marakalala, Dr. Nkateko

Mkhondo

ENTERTAINMENT

PRESENTER	TOPIC
MMC Siyabonga Moloi City of Ekurhuleni Municipality	Welcoming delegates to Ekurhuleni
Prof. Mohlopheni Jackson Marakalala Conference Chair, South African Medical Research Council & Dr. Nkateko Mkhondo Conference Co-Chair, Senior Public Health Specialist	Delivery of the Opening address.
Prof. Mosa Moshabela Vice-Chancellor and Principal, University of Cape Town	The role of national health research and academic leadership in strengthening TB research and health systems.
Prof. Grant Theron Professor, Stellenbosch University	TB Transmission and emerging diagnostic approaches.
Dr. Dennis Falzon Public Health Specialist and Epidemiologist, World Health Organization (WHO)	Emerging developments in TB prevention and care (recorded).
Prof. Kogie Naidoo Deputy Director, CAPRISA	Sustaining momentum to end TB.
ENTERTAINMENT	
Ms. Ntswaki Mosia-Motaung TB Ambassador, Person with lived experience	Reflections on a personal journey through TB.
Dr. Pakishe Aaron Motsoaledi Minister of Health, National Department of Health, Republic of South Africa	Keynote address.



9 June 2026

Plenary Speaker Biographies



Prof. Neil Martinson

Executive Director, Perinatal HIV Research Unit (PHRU)

Prof Neil Martinson heads the Perinatal HIV Research Unit (PHRU). He graduated as a physician from the University of the Witwatersrand, Johannesburg. He has over 20 years of managerial, and research experience in HIV and TB. His research work includes: preventing TB and measuring its interactions with HIV; viral drug resistance selected by PMTCT programs; case finding for TB in HIV-infected pregnant women and household contacts of a TB case. He has undertaken four large studies of household contact tracing, using index cases of a variety of different types who either had TB disease or TB infection. He has published several studies assessing the value of active case finding using different methods of diagnosis. He has experience in design and implementation of both individually and cluster randomised trials and while he continues to conduct research in Soweto, he has also built a large research platform in Matlosana and Limpopo Province, both areas with and HIV/TB problem in South Africa. His current research thrust is measuring reductions in mortality, morbidity and transmission of TB.



Mr. Russell Rensburg

Director, Rural Health Advocacy Project (RHAP)

Russell Rensburg is a health activist working towards equitable health access to quality health care for rural and underserved communities and currently serves as an Executive Director for the Rural Health Advocacy Project and the TB Accountability Consortium. He has over 15 years' experience working on strengthening health systems, with 8 of those spent managing technical assistance in Eastern and Southern Africa.

He has a strong interest in strengthening the responsiveness of public finances towards equitable health access. He has served as a commissioner on the South Africa Lancet Commission for Quality Health Systems and the ministerial task team that developed the National Human Resources for Health Strategy. He currently serves as a community representative on the SA Nursing Council, co-chairs the SANAC CSF TB Technical Task Team and is a member of the ministerial advisory committee health benefits package.



Prof. Ali Esmail

Professor, University of Cape Town

Prof Ali Esmail is a specialist physician and an interventional pulmonologist based at Groote Schuur Hospital in Cape Town, South Africa. He serves as the Deputy Head of the Centre for Lung Infection and Immunity at the University of Cape Town Lung Institute and is a principal investigator on several clinical trials focused on TB (TB) and related conditions across Africa. Prof Esmail has a PhD in TB diagnostics and is currently involved in several clinical trials evaluating novel TB vaccines. Prof Esmail is also a founding member for the charity 'Free-of-TB' which promotes the health, well-being and interests of patients with TB.



9 June 2026

Plenary Session 1: From Bench to Community: Diagnostic Advances to End TB

Time: 09:00 – 10:30
Venue: OR Tambo
Session Chair: Dr. Shaheed Vally Omar

PRESENTER	TOPIC
<p>Prof. Neil Martinson Executive Director, Perinatal HIV Research Unit (PHRU)</p>	<p>Diagnostic Innovation in Action. The TUTT story: Pooling and swabbing strategies to improve access and reach populations currently missed. Laboratory advances that scale.</p>
<p>Prof. Ali Esmail Professor, University of Cape Town</p>	<p>Clinical Imperatives: Why Early Diagnosis Matters. How diagnostics shape patient management. The cascade from early detection to limiting transmission, reducing morbidity, and preventing mortality. Access as a clinical determinant.</p>
<p>Mr. Russell Rensburg Director, Rural Health Advocacy Project (RHAP)</p>	<p>Civil Society and the Diagnostic Ecosystem. Using public data to drive demand in key populations. Diagnostics as part of the solution, not the solution. Sustainability in resource-constrained settings. Aligning health workers, communities, and programmes to collectively end TB.</p>

MORNING BREAK



9 June 2026

Plenary Speaker Biographies



Prof. Jason Farley

Associate Dean, Johns Hopkins University School

Prof Jason Farley is a nurse clinician-scientist who has worked in TB/HIV in the US and in South Africa for over 20 years. In close collaboration with NDoH and multiple SA University colleagues, his team has focused

on developing strategies to enhance patient outcomes for people with DR-TB. He is a Professor at Johns Hopkins University with an adjunct faculty appointment at UKZN. He maintains an active HIV and HIV prevention clinical practice at the John G. Bartlett Infectious Disease Specialty Clinic in Baltimore, Maryland. He has more than 140 peer reviewed publications and has received funding from multiple US and SA funding agencies.

medical students. Dr. Perumal holds an MBChB from the University of KwaZulu-Natal, an MPH in Public Health Medicine, and an MMed in Internal Medicine. He is a Fellow of the College of Physicians of South Africa and a PhD candidate at UKZN. His research centres on TB epidemiology and health systems strengthening, with a focus on integrated TB and HIV service delivery in co-epidemic settings.



Prof. Norbert Ndjeka

Chief Director for TB Control and Management, National Department of Health, Republic of South Africa

Prof Norbert Ndjeka is the Chief Director for TB Control and Management at South Africa's National Department of Health.

A specialist family physician with expertise in TB (TB) and HIV, he has played a leading role in strengthening South Africa's response to drug-resistant TB and improving treatment outcomes nationally.



Prof. Rubeshan Perumal

Associate Professor of Clinical Medicine, University of KwaZulu-Natal

Dr. Perumal is a Consultant Physician and Fellow in the Department of Pulmonology and Critical Care at the University of Cape Town, where he is involved in

the development and delivery of specialist respiratory and critical care services. He also plays an important role in the training of undergraduate medical students in Internal Medicine, Pulmonology, and Critical Care, contributing to the development of future clinicians. In addition, he is part of the leadership team for specialised clinics and outreach services focused on the management of complex drug-resistant TB cases.

He is a Scientific Research Associate at the Centre for the AIDS Programme of Research in South Africa, where his work focuses on TB and HIV research, alongside mentorship of junior researchers and

Prof. Ndjeka has contributed extensively to TB policy, research, and guideline development across Africa, and has authored numerous peer-reviewed scientific publications. He currently serves as Chairperson of the African Green Light Committee (Afro-GLC), which advises the World Health Organization on the management of drug-resistant TB, and is President of the End TB SADC Committee. In recognition of his contribution to global TB control, he received an honorary doctorate from the University of Cape Town and was appointed Honorary Associate Professor of Medicine at the University of Cape Town.



9 June 2026

Plenary Speaker Biographies



Prof Max O'Donnell

Associate Professor of Medicine,
Columbia University Irving Medical
Center

Max O'Donnell, MD, MPH, is Associate Professor
of Medicine and Epidemiology at Columbia
University, NY, NY, USA. His research focuses on
drug-resistant tuberculosis, TB/HIV, treatment

adherence, emerging TB drug resistance, and global lung health. He has
longstanding collaborations in South Africa, including with CAPRISA and the
University of KwaZulu-Natal.

He leads NIH-funded translational and clinical research aimed at improving
diagnosis, treatment, and outcomes for drug-resistant TB.



Dr. Anushka Naidoo

Senior Researcher, CAPRISA

Anushka Naidoo is a South African
researcher and scientist known for her work
in TB (TB), HIV, implementation science, and
public health research.

Dr Naidoo has worked with several
major public health and research institutions in South Africa and
internationally. Her work focuses on improving healthcare delivery
systems and patient outcomes in infectious diseases.

She has been involved in TB and HIV programme implementation,
clinical and operational research, health systems strengthening, and
epidemiology and public health policy research.



9 June 2026

Plenary Session 2: Therapeutic Advances – Implications for TB programme Implementation

Time: 11:00 – 12:30
Venue: OR Tambo
Session Chair: Prof. Kogje Naidoo,
Dr. Marian Loveday

PRESENTER	TOPIC
Prof. Jason Farley Associate Dean, Johns Hopkins University School of Nursing	Results from the BPAL2Me study.
Prof. Rubeshan Perumal Associate Professor of Clinical Medicine, University of KwaZulu-Natal	Are we ready for a PAN TB regimen? Novel DR-TB drugs and regimens.
Prof Max O'Donnell Associate Professor of Medicine, Columbia University Irving Medical Center	Latent Class Membership and Medication Adherence as Independent Predictors of Outcomes in Drug-Resistant TB/ HIV Treatment.
Prof. Norbert Ndjeka Chief Director, National Department of Health, Republic of South Africa	Analysis of Determinants of Rifampicin-Resistant TB Treatments outcomes in South Africa.
Dr. Anushka Naidoo Senior Researcher, CAPRISA	The implications of the Lenacapavir roll-out in the context of TB treatment and prevention in South Africa.

Satellite Session

Minerals Council South Africa: Occupational Lung Diseases in Mining: Partnerships, Prevention, and Diagnostic Advances

Time: 11:00 – 12:30
Venue: King Shaka

LUNCH BREAK – EXHIBITION + POSTERS (12:30 – 14:00)



9 June 2026

Track 1, Session 1: Clinical & Programmatic DR-TB

Time: 14:00 – 15:30

Venue: OR Tambo

Session Chair: Prof. Ebrahim Variava

Co-Chair: Ms. Jacqueline Ngozo

SPEAKER	TOPIC
Ms. Lavania Joseph NICD/NHLS	Genetic basis of resistance to BPaL regimen drugs in mycobacterium TB: continued genotypic–phenotypic characterisation in South Africa.
Dr. Nothile Hlongwane National Department of Health, South Africa	Clinical audit of patients with MDR TB in tertiary hospital.
Dr Farzana Ismail National Institute for Communicable Diseases	Bedaquiline, pretomanid, and linezolid resistance among rifampicin-resistant M. TB strains in South Africa.
Dr. Yonas Ghebrekristos Green Point TB Laboratory	Bedaquiline and linezolid resistance in people with rifampicin-resistant TB in the Western Cape Province of South Africa.
Ms. Sinothando Dlamini University of the Witwatersrand	Effects of pyrazinamide and/or ethambutol resistance detected by whole genome sequencing on TB treatment outcomes, South Africa 2020 – 2022.

Track 3, Session 1: Harnessing AI Across the Cascade

Time: 14:00 – 15:30

Venue: Auditorium

Session Chair: Dr. Elias Ramarumo

Co-Chair: Dr. Lynette Duckworth

SPEAKER	TOPIC
Ms. Tanyaradzwa Dube The Aurum Institute	Implementing an AI-powered digital treatment supporter for TB care in South Africa: early experience from Ekurhuleni and Bojanala districts.
Ms. Farzana Sathar TB Think Tank	Optimising digital chest x-ray for tb screening: evidence to inform a practical implementation toolkit.
Dr. Joao Pedro Neves Delft Imaging B.V.	Performance of a paediatric computer-aided detection system for chest x-ray interpretation in TB screening.
Dr. Batanayi Muzah Private	Beyond triage: the evolving role of artificial intelligence in TB diagnostics and treatment optimization: a 2024-2026 synthesis.
Prof. Brittney van de Water Connell School of Nursing	Heterogeneity across 16 facilities: TB cascade performance prior to the systems analysis and improvement approach for tb (saia-tb) implementation in Eastern Cape, South Africa.



9 June 2026

Track 4, Session 1 : TB Policies and guidelines

Time: 14:00 – 15:30
Venue: Marco Polo
Session Chair: Dr. Thato Chidarikire
Co-Chair: Mr. Russell Rensburg

SPEAKER	TOPIC
Mr. Christofer van Rooyen Social Development	End TB Strategy Department of Social Development 2025-2028.
Ms. Ingrid Schoeman TB Proof	Improving access to TB care for contacts of people with TB: piloting TB contact cards in Khayelitsha health facilities.
Mr. Dumisani Madhlophe Sungulo Community Organisation	Harnessing eco therapy to mitigate burnout amongst community care workers and nurses in resource-limited settings.
Ms. Aline Mukeshimana St Josephs Children Hospital	Role of intermediate paediatric care in the effort to combat TB.
Dr. Masindi Mashapha Department Of Social Development	The effect of intradepartmental and multisectoral collaboration in the mitigation of the catastrophic costs of tuberculosis: An initiative of the Department of Social Development.
Mrs Nobesuthu Ramawela Department of Health	Development of the TB Quality Improvement (QI) Implementation Guide: A Standardized Strategy to Strengthen TB Case Finding and Improve the TB Care Cascade in South Africa

Satellite Session

RHAP: Making every rand count: Strengthening district-level TB services through smarter grant use.

Time: 14:00 – 15:30
Venue: Heathrow

Track 2, Session 1: Clinical Trials of novel TB drugs and regimens (including PK abstracts)

Time: 14:00 – 15:30
Venue: Barcelona
Session Chair: Dr. Lindiwe Mvusi
Co-Chair: Dr. Boitumelo Fanampe

SPEAKER	TOPIC
Dr. Morounfolu Olugbosi TB Alliance, South Africa	Week 8 interim analysis of NC-009 trial: safety and efficacy of sorfequiline combined with pretomanid and linezolid.
Ms. Judicious Nethavhani Sefako Makgatho Health Sciences University	Antimycobacterial effect of a new antitubercular drug candidate SQ109 against clinically relevant non-tuberculous mycobacteria.
Mr. Gcina Sawuka Treatment Optimization Campaign	PRISM-TB trial aims to optimize treatment for drug-resistant TB with personalized approach.
Dr. Elri Nortier Desmond Tutu TB Centre	Pharmacokinetics and safety of a novel clofazimine formulation and dosing strategy in children with rifampicin-resistant TB.
Dr. Pauline Howell Clinical Health Research Unit	IMPAACT 2034: phase 1 study of the pharmacokinetics (PK), safety/tolerability and acceptability of a single dose of pretomanid in female children with rifampicin resistant TB (RR-TB).

Satellite Session

ABBOTT

Time: 14:00 – 15:30
Venue: Cape Town International

Satellite Session

SAHTAC: Investment for TB Innovation: Aligning Sustainable Financing with High-Impact TB Programme Strategies in South Africa

Time: 14:00 – 15:30
Venue: Charles De Gaulle



9 June 2026

AFTERNOON BREAK - EXHIBITION + POSTERS (15:30 - 16:00)

Track 1, Session 2: Diagnostics & Implementation

Time: 16:00 - 17:30
Venue: OR Tambo
Session Chair: Dr. Shaheed Vally Omar
Co-Chair: Prof. Nazir Ismail

SPEAKER	TOPIC
Dr. Boitumelo Fanampe Department of Health, Free State	DNA from used Xpert MTB/RIF ultra cartridges obtained using the credo extraction device reduces drug-resistant TB care cascade gaps in a routine laboratory.
Ms. Fredricka Mkwanazi Isibani Development Partners	Integrated pairing of NHLS genexpert mobile services and mobile digital chest x-ray within the communities for accelerated TB detection and linkage to care.
Ms. Orah Rikhotso Sefako Makgatho Health Sciences University	Comparison of BD MAX MDR-TB assay with genexpert MTB/rif ultra-assays and target sequencing for the detection of mycobacterium TB complex and rifampicin drug resistance in clinical specimens sent to a tertiary laboratory in Pretoria.
Dr. Nina von Knorring National Health Laboratory Service	Validating the Roche cobas 6800 MTB and MTB-RIF/INH assays for mycobacterial cultured isolates.
Ms. Mmule Kim Mathebe University of Limpopo	Comparative evaluation of the Xpert MTB/XDR and fluorotype XDR assays for detecting fluoroquinolone resistance in clinical multidrug-resistant TB isolates.
Ms. Rirhandzu P Mkhari University of Cape Town	Tongue swab and oral rinse for the diagnosis of symptomatic and asymptomatic pulmonary TB using Xpert MTB/RIF ultra.

Track 2, Session 2: Optimising TB outcomes in children and adults

Time: 16:00 - 17:30
Venue: Cape Town International
Session Chair: Dr. Josephine Otchere-Darko
Co-Chair: Dr. Thando Maseko

SPEAKER	TOPIC
Ms. Keneilwe Nkoana Free State Department of Health	High Mortality at a DR-TB Admission Facility in Mangaung, Free State Province, South Africa
Ms. Thuso Mafhungo Mpumalanga Department of Health	Factors associated with unsuccessful TB treatment outcomes among patients in Msukaligwa Sub-District, Mpumalanga Province: 2019-2023.
Mr. Davie Zenengeya Paradiso TB Patients Trust	Integrating Pulmonary rehabilitation into routine TB care to improve Post-TB recovery in Malawi.
Dr. Anushka Naidoo CAPRISA	Bictegravir for the treatment of HIV-Associated TB- Findings from the INSIGHT Trial.
Prof. Mo Archary University of KwaZulu Natal	Simplifying TB-HIV Co-infection treatment in children with HIV: Orchid study.
Mr. Ruben van de Venter University of Cape Town	Twice-Daily Dolutegravir With a 4-Month Rifapentine-Based Regimen for HIV-Associated Tuberculosis.



9 June 2026

Track 3, Session 2: New Tools, New Models, New Hope

Time: 16:00 - 17:30
Venue: Auditorium
Session Chair: Mrs. Leisha Genade
Co Chair: Ms. Jacqueline Ngozo

SPEAKER	TOPIC
Mr. Kenny Sithole Clinton Health Access Initiative	From COVID-19 Ag-RDTs to pluslife minidock: leveraging rapid test introduction experience for near point-of-care TB diagnosis in Zimbabwe.
Ms. Nompumelelo Ngobese Africa Health Research Institute	Evaluation of the role of tongue swabs to optimize Tutt implementation - an observational study (TUTT Plus).
Mrs. Mhlamonyane Mbali Perinatal HIV Research Unit	Beyond Sputum: Perceptions of Emerging TB diagnostics in South Africa through the TUTT Plus study.
Dr. Ashleigh Dwarika Isibani Development Partners	Breaking down barriers to tb diagnosis in the private healthcare sector: a public-private partnership model from Ekurhuleni Health District, South Africa.
Dr. Logandran Naidoo AIDS Healthcare Foundation	Automated medication dispensing through prescription collection units: client perspectives from a primary health care clinic in Umlazi, KwaZulu-Natal.
Dr. Thobeka Dlangalala University of Pretoria	Developing an Approach for Enhancement of TB Diagnostic Services during the Pandemic: A case of Primary Health Care Clinics in eThekweni District KwaZulu-Natal.

DINNER BREAK (17:30 - 18:00)

Satellite Session

RHAP: Evening Function

Time: 18:00 - 19:30
Venue: King Shaka



10 June 2026

Plenary Speaker Biographies



Prof. Violet Chihota
Group Chief Scientific Officer
The Aurum Institute

She has previously worked as a Senior Scientific Officer at Foundation for Innovative New Diagnostics (FIND), Switzerland. She is also an Adjunct Associate Professor at the Department of Medicine in the Vanderbilt

University School of Medicine and a Senior Researcher at University of Witwatersrand, School of Public Health.

Prof Chihota holds a BSc Honours Biological Sciences from the University of Zimbabwe, an MSc Medical Microbiology from London School of Hygiene and Tropical Medicine, a PhD in Medical Biochemistry from Stellenbosch University and has training in Epidemiology and Statistics from the Johns Hopkins University. She has straddled both the basic science, epidemiology and implementation research fields.

Her work has focused on epidemiology of TB, evaluating TB diagnostic tools and strategies for improving health outcomes in people with TB in Southern Africa region. Her current interests include diagnosis and treatment of latent TB infection (LTBI) and resistance to TB infection. She is also a skilled manager of complex interventional implementation research projects having managed and worked with diverse teams at both Aurum Institute and FIND. Prof. Chihota has published widely on HIV/TB coinfection particularly focusing on molecular epidemiology of drug sensitive- and resistant- TB, diagnosis, case finding and linkage to care.



Mr. Braden van Breda
CEO, AI Diagnostics

After developing cardiac implants and equipment for specialist interventions, Braden co-founded AI Diagnostics to develop diagnostic solutions for the other end of the healthcare funnel, primary healthcare workers. AI Diagnostics' flagship

product accurately detects TB by analyzing patients' lung sounds captured on their easy to use AI enabled stethoscope.



Dr. Boitumelo Seepamore
Lecturer, University of KwaZulu-Natal

Boitumelo Seepamore is a lecturer at the University of KwaZulu-Natal, South Africa. She is an experienced public health social worker and qualitative researcher working in the field of Drug-resistant TB and HIV.

Her work in South Africa examines public health social work interventions, palliative care, psychosocial support, caregiving practices and adherence in vulnerable and stigmatised populations particularly in TB care. Boitumelo currently participates in a randomized control adherence intervention trial for people with DR-TB HIV in KwaZulu-Natal, and works closely with other organisations and groups in public health.



Dr. Elias Ramarumo
Director, National Department of Health, Republic of South Africa

Dr. Nдавheleseni Elias Ramarumo is the Director for Monitoring, Evaluation, Reporting and Learning (MERL) in the Global Fund Cluster at the National Department of Health, South Africa. With over 20 years of

experience in public health and development, he leads national MERL systems for HIV/TB programmes funded by the Global Fund. Driven by a strong commitment to global sustainable development, Dr. Ramarumo thrives in collaborative, multidisciplinary environments and actively seeks partnerships that foster learning, innovation, and impact. My professional philosophy is captured in a guiding belief: "When others say it cannot be done, I ask—when can I start?"



10 June 2026

Plenary Session 3: Implement Intelligently: Evidence-Based Integration for Impact

Time: 09:00 – 10:30
Venue: OR Tambo
Session Chair: Prof. Limakatso Lebina,
Dr. Mamothe Makgabo

ENTERTAINMENT

PRESENTER	TOPIC
Prof. Violet Chihota Group Chief Scientific Officer, The Aurum Institute	Closing the Gaps at the Point of Entry: Diagnostics for Early TB Detection and Linkage.
Mr. Braden van Breda CEO, AI Diagnostics	Digital Stethoscope.
Dr. Boitumelo Seepamore Lecturer, University of KwaZulu-Natal	Compassion requires support: Rethinking patient-centred care.
Dr. Elias Ramarumo Director, National Department of Health Republic of South Africa, Global Fund Cluster	Closing the TB Detection Gap: Leveraging Digital Chest X-Ray and AI for Enhanced TB Screening in South Africa.

MORNING BREAK (10:30 – 11:00)

Track 1, Session 3: Diagnostics / Innovation Focus

Time: 11:00 – 12:30
Venue: OR Tambo
Session Chair: Dr. Siphon Nyathi
Co-Chair: Dr. Boitumelo Fanampe

SPEAKER	TOPIC
Dr. Christopher Ealand University of the Witwatersrand	Performance of tongue swabs for TB diagnosis in hospitalized children under 5 years of age.
Ms. Alaina Olson University of Washington	Comparison of pluslife minidock MTB, a commercial, automated TB testing platform, to a manual, high-sensitivity, laboratory ideal for use with tongue swabs.
Ms. Thabiso Seiphetlo Perinatal HIV Research Unit	Rethinking sputum quality: diagnostic yield of "salivary" specimens collected after forced cough effort for TB nucleic acid amplification testing.
Dr. Atang Bulane Centre for TB	Pooling sputum specimens of people at high-risk of TB reduces testing burden without compromising diagnostic concordance. The TUTT Plus Study.
Mr. Mathee Ramushu Health Economics & Epi-Wits	Pooling sputum specimens of people at high risk of TB reduces costs of xpert ultra TB testing: results from the TUTTPlus study in South Africa.
Dr. Juli Switala The Aurum Institute	Impact of stool-based TB testing on TPT initiation among child contacts of TB patients: a nested cross-sectional study in Ekurhuleni, South Africa.
Dr. Jaumdally Shameem UCT Lung Institute	Bacterial and host determinants of cough aerosol culture-positivity in minimally symptomatic or asymptomatic patients with tuberculosis diagnosed during community-based active case finding.

Track 2, Session 3: Preventing TB in close contacts

Time: 11:00 – 12:30
Venue: King Shaka
Session Chair: Prof. Violet Chihota
Co-Chair: Prof. Desh Archary

SPEAKER	TOPIC
Ms. Lauren Brown Sacema	TB incidence among household contacts of individuals with symptomatic and asymptomatic TB: a retrospective cohort study in the Western Cape province of South Africa.
Ms. Jeniffer Nagudi The Aurum Institute	Determinants of TB preventive therapy uptake and completion amongst caregivers of child contacts across three high TB burden countries.
Ms. Sonnet Modisane West Rand District	Barriers to TB preventive therapy uptake among contacts in a high-burden district: evidence from West Rand, South Africa.
Mr. Freck Dikgale Aquty Innovations	Performance of digital chest X-Ray (DCXR) for TB (TB) case finding in Tonga Hospital, Nkomazi sub-district in Ehlanzeni.



10 June 2026

Track 3, Session 3: Person-Centred TB Care for Vulnerable Populations

Time: 11:00 – 12:30
Venue: Auditorium
Session Chair: Dr. Matsie Mphahlele
Co-Chair: Dr. Louisa Dunn

SPEAKER	TOPIC
Prof. Karen du Preez Stellenbosch University	Modelling the COVID-19 pandemic impact on the diagnosis of child and adolescent TB in South Africa.
Dr. Mohlala Kwalabotseng Health	Targeted universal TB testing (TUTT) at first antenatal visit: implementation outcomes from Boikhutsong primary health care clinic, Tshwane district health region 1.
Mrs. Genade Leisha Perinatal HIV Research Unit	Laboratory-confirmed TB in outpatients at high risk for TB: with and without diabetes mellitus in the TUTT Plus Study.
Mrs. Thoko Tsela Department of Health, Mpumalanga	Health-seeking behaviour among patients attending TB care at health facilities in a rural sub-district of Mpumalanga province, South Africa.
Dr. Katlego Motlhaoleng University of Cape Town	Determinants of drop-offs in the targeted universal tuberculosis testing care cascade among people with HIV in rural and urban facilities in South Africa.
Ms. Mabusi Kgwete Centre for Community Development South Africa	Extrapulmonary TB treatment literacy and health system readiness: a survivor-led assessment of primary health care gaps and community misconceptions in South Africa.

Track 4, Session 2: TB responses and sustainability

Time: 11:00 – 12:30
Venue: Marco Polo
Session Chair: Dr. Regerio Phili
Co-Chair: Dr. James Ndirangu

SPEAKER	TOPIC
Prof. Fareed Abdullah South African Medical Research Council	Building an ecosystem for innovative financing for sustainability in TB financing.
Ms. Nelisiwe Mhlabane NIFDAR PBO	Sustaining TB Programme Performance in a resource-constrained setting: using routine data to identify efficiency gaps in West Rand District, South Africa.
Dr. Lee-Ann Davids South African Medical Research Council	A scoping review of non-pharmacological interventions to improve rifampicin-resistant TB outcomes in high burden MDR/RR-TB countries.
Ms. Boitumelo Moloisane Reach What You Preach Foundation	The role of Faith Based Organisations in HIV & TB response: a theological and public health response to TB and HIV co-infection in South Africa.
Ms. Hlengiwe Pretty Nyilana CAPRISA SCRC	The feasibility and potential of Theory-informed Social Work Interventions for people with TB and HIV: Insights from the ADAP-TIV Study in South Africa.

Satellite Session

Health Systems Trust: Strengthening TB Services: Leveraging Innovation and Implementation Science to Improve TB Programmes

Time: 11:00 – 12:30
Venue: Heathrow

Satellite Session

The Aurum Institute: Satellite Session

Time: 11:00 – 12:30
Venue: Barcelona

Satellite Session

Inqaba Biotec: Beyond TB: Integrating Molecular Diagnostics and NTM Intelligence for Smarter Disease Control.

Time: 11:00 – 12:30
Venue: Cape Town International

Satellite Session

Molbio Diagnostics: Harnessing experiences from the introduction of Truenat to transform the quality of TB/DRTB management in the Africa Region.

Time: 11:00 – 11:30
Venue: Charles De Gaulle

LUNCH BREAK – EXHIBITION + POSTERS (12:30 – 14:00)

10 June 2026

Track 1, Session 4: Biology / Mechanisms Focus

Time: 14:00 – 15:30

Venue: OR Tambo

Session Chair: Dr. Elias Ramarumo

Co-Chair: Dr. Lindiwe Mvusi

SPEAKER	TOPIC
Mrs. Tejashree Jivan WITS University/NICD	Minimum inhibitory concentration of mycobacterium TB isolates with mutations associated with who interim resistance to rifampicin, isoniazid and fluoroquinolones.
Ms. Nonhlanhla Mabuza University Of Cape Town	Peripheral whole-blood gene expression biomarkers for distinguishing tuberculous lymphadenitis from B-cell lymphoma.
Mr. Pleasure Malope National Institute For Communicable Diseases	Bedaquiline resistance associated genetic mutations and minimum Inhibitory concentrations in drug-resistant TB clinical isolates in Limpopo province, South Africa.
Ms. Astika Sewcharran University Of The Witwatersrand	Differentially culturable mycobacterium TB reveals hidden transmission dynamics in South African households.
Dr. Halima Said National Institute for Communicable Diseases (NICD)	Evaluation of Deeplex Myc-TB assay against whole genome sequencing for MTBC lineage determination.
Dr. Unarine Matodzi University of Pretoria	Patterns of drug resistance, drug resistance conferring mutations and genomic DNA methylation revealed in mycobacterium tuberculosis from South Africa.

Track 4, Session 3: Elimination of social, structural and service delivery enablers

Time: 14:00 – 15:30

Venue: King Shaka

Session Chair: Mr. Pholokgolo Ramothwala

Co-Chair: Mr. David Macana

SPEAKER	TOPIC
Mr. Karabo Sekgale North West Provincial Council On Aids	Implementation performance of the multi-sectoral collaboration in combating the public health threat of infectious diseases in North West Province, South Africa.
Mr. Makanda Goodman TB Proof	A Whole-of-society approach to TB care: community-led monitoring in Khayelitsha.
Mr. Sizwe Mthabela University of Pretoria	Mapping evidence on the association between nutritional status and nutrition-related knowledge, attitudes, and practices among people receiving TB treatment in Sub-Saharan Africa.
Mr. Ludick Mabyane Civil Society Forum	Ensuring sustainable TB services for key populations amid funding constraints: Lessons from community-led engagement in North West Province, South Africa.
Dr. Edwin Moalosi Institute of Health Programs and Systems	The Impact of Decentralising DR-TB Services on second-line treatment coverage and treatment outcomes in the Dr Kenneth Kaunda Health District, South Africa.

Track 3, Session 4: From Survival to Quality of Life: Post-TB Care Matters

Time: 14:00 – 15:30

Venue: Auditorium

Session Chair: Dr. Katlego Motlhaleng

Co-Chair: Dr. Farzana Ismail

SPEAKER	TOPIC
Dr. James van Duuren Africa Health Research Institute	TB related health impairment at end of treatment assessed using the st. George's respiratory questionnaire: uMkhanyakude District, South Africa.
Ms. Claudine Bill The Health Foundation	Impact of drawing the TB treatment action list (TTAL) at primary healthcare clinics in cape town to identify and link hospital diagnosed tuberculosis patients to care.

10 June 2026

Ms. Motsei Sebole Aquity Innovations	Post-TB lung disease in a South African mining community: prevalence, clinical characteristics, and implications for integrated lung health screening.
Ms. Letitia Rambally Greener Population Services International	Beyond the Clinic: leveraging ai to bridge psychosocial gaps in the South African TB care cascade.
Dr. Matthys Potgieter EPCON SA (Pty) Ltd	Testing-adjusted, nationally calibrated TB hotspot ranking for health sub-districts with EA-level vulnerability targeting in South Africa based on TB Naat testing.

SA Provincial Showcase Session

Time: 14:00 - 15:30
Venue: Marco Polo
Session Chair: Ms Jacqueline Ngozo

SPEAKER	TOPIC
Ms Modipadi Mugivhi Gauteng	The Gauteng Department of Health utilize health Care workers as an investment, not a cost.
Dr Avashri Harrichandparsad KZN	The cost of primary healthcare services for drug-susceptible tuberculosis in adults in KwaZulu-Natal in 2025 using time-driven activity-based costing
Mr Vincent Blaar Northern Cape	The influence of Mine Partnership on Tuberculosis Programme in Northern Cape
Ms Zanele Radebe KZN	Stopping TB and other childhood illnesses in children campaign: Multi-sectoral approach (DoH, OTP, DOE & DSD)
Ms Fikisiwe Mdabe KZN	Reducing Sputum Rejection Rates through Implementation of a Quality Improvement plan at Pinewood Clinic

Satellite Session

RHAP: From the ground up: Embedding South Africa's TB champions in the national response

Time: 14:00 - 15:30
Venue: Heathrow

Satellite Session

SAMRC: South Africa's evolving innovative financing landscape to fund TB

Time: 14:00 - 15:30
Venue: Barcelona

Satellite Session

Department of Social Development: DSD's National TB Response: Integrating Prevention, Social Protection, and Psychosocial Support Services

Time: 14:00 - 15:30
Venue: Cape Town International

AFTERNOON BREAK - EXHIBITION + POSTERS (15:30 - 16:00)

Track 1, Session 5: Host Response & Treatment Biology

Time: 16:00 - 17:30
Venue: OR Tambo
Session Chair: Dr. Chris Ealand
Co-Chair: Mr. Mncedisi Madlavu

SPEAKER	TOPIC
Dr. Junaid Shaik Durban University of Technology	Biomarker signatures for the diagnosis and monitoring responses to anti-TB treatment among children with genexpert positive TB.
Mr. Gogela Ndiitwani Noel Sefako Makgatho Health Sciences University	Phenotypic and genotypic characterization of bedaquiline and clofazimine resistance in drug-resistant mycobacterium TB isolates at a tertiary laboratory in Pretoria, South Africa.
Dr. Pholo Maenetje The Aurum Institute	Longitudinal inflammation cytokine trajectories during TB and their association with lung outcomes.
Dr. Welcome Maepa South African Medical Research Council	Understanding mediators of TB associated lung pathological damage to aid designing of host-directed therapies.
Dr. Kudakwashe Nyambo Stellenbosch University	Leveraging machine learning for drug repurposing and synthesizing rhodium-based therapeutics.



10 June 2026

Track 1, Session 6: Short Oral Communication Translational and Diagnostic Advances in TB

Time: 16:00 – 17:30
Venue: Barcelona
Session Chair: Dr. Shaheed Vally Omar
Session Co Chair: Prof. Neil Martinson

SPEAKER	TOPIC
Ms. Ontefetse Plaatjie North West Univeristy, Potchefstroom Campus	LC-MS metabolomics of cerebrospinal fluid in paediatric tuberculous meningitis.
Dr. Robinah Nakawunde Stellenbosch University	Hidden lung impairment at TB diagnosis: a comprehensive physiological and imaging assessment.
Dr. Sarishna Singh National Health Laboratory Service	Now you see it isoniazid resistant TB emerging from diagnostic oversight.
Dr. Awelani Mutshembele South African Medical Research Council	Antimycobacterial activity and transcriptomic responses of mycobacterium TB H37RV exposed to piper betel-derived phytochemicals.
Discussion	
Ms. Eisha Abbasi National Institute for Communicable Diseases, National Health Laboratory Service	Developing a real-time PCR using high resolution melt analysis for detection of bedaquiline resistance.
Mrs. Chandni Madhav Wits Health Consortium	Host determinants of mycobacteriophage infection: implications for phage-based therapy in drug-resistant TB.
A/Prof. Bhavna Gordhan National Health Laboratory Service/ University of the Witwatersrand	Clinical strains of mycobacterium TB exhibit distinct propensities to adopt the differentially culturable state.
Ms. Yasmin Gardee CTB, NICD/NHLS	New and repurposed TB drugs – keeping up with changes, a quality assurance perspective.
Ms. Loren Rockman Stellenbosch University	Diagnostic accuracy of pluslife minidock MTB on tongue swabs and sputum swabs in sputum scarce people with presumptive TB: a retrospective analysis.

Track 2, Session 4: Diagnostic and Clinical Phenotypes of DR-TB Outcomes

Time: 16:00 – 17:30
Venue: King Shaka
Session Chair: Dr. Jacob Attie Stadler
Co-Chair: Prof. Rubeshan Perumal

SPEAKER	TOPIC
Ms. Lebogang Ndlovu Sefako Makgatho Health Sciences University	Phenotypic and molecular investigation of MTB isolates with drug resistance in bedaquiline and clofazimine naïve patients.
Dr. Rodolfo Romero Department of Health, Northern Cape	Use of carbapenems in XDR TB with limited options to improve outcomes.
Ms. Kynesha Moopanar Research Assistant	Longitudinal analysis of prevalence and risk factors of cavitary lung disease in people with drug-resistant TB.
Dr. Suzette Oelofse UCT Lung Institute	Linezolid interruption and rechallenge in RR-TB in South Africa.
Mr. Murungi Baguma Nelson Mandela University	Development of Multifunctional Nanomedicines for the Targeted Treatment of Drug-Resistant Pulmonary TB.

10 June 2026

Track 3, Session 5: From Paper to Practice: Delivering TB Impact at Scale - Facility and Community

Time: 16:00 – 17:30
Venue: Auditorium
Session Chair: Dr. Prida Subrayen
Co-Chair: Dr. Thandi Dlamini Miti

SPEAKER	TOPIC
Ms. Monica Longwe National Department of Health/ Genesis Analytics	Co-Creating the End TB Campaign to Build a People-centred SBCC ecosystem in South Africa.
Mrs. Yulene Kock National Department of Health	Multidisciplinary data quality workshops drive improved DR-TB treatment success in South Africa.
Mrs. Nombuyiselo Mofokeng Perinatal HIV Research Unit	Missed opportunities: high yield of universal TB testing in emergency department patients and companions in Botshabelo Hospital in the Free State.
Mrs. Van Niekerk Margaret-Antoinette Stellenbosch University, Desmond Tutu TB Centre	Longitudinal food insecurity and nutritional status among children with respiratory illness and TB in Cape Town, South Africa.
Discussion	
Ms. Rita Gachiri Kenya Aids Ngos Consortium	Engaging traditional healers to improve TB case notification in Kenya: evidence from a community-based referral model.
Ms. Claudine Bill Western Cape Government Health and Wellness	Increasing TB testing in the Cape Town (CT) metro: community health workers are key partners in implementing targeted universal TB testing (TUTT).
Mr. Ndumiso Tshuma Best Health Solutions	The mediating role of civil society sustainability in linking operational capacity to community systems strengthening in South Africa: a structural equation modelling analysis.
Mr. Madalitso Mmanga National TB and Leprosy Elimination Program	To Integrate or not to integrate: effects of service integration on uptake and sustainability of community TB screening programs, in Malawi.
Ms. Natasha Singh NICD	The detection and quantification of Mycobacterium TB in wastewater samples.

Track 2, Session 5: Preventing and Treating Paediatric TB

Time: 16:00 – 17:30
Venue: Marco Polo
Session Chair: Dr. Karen du Preez
Co-Chair: Dr. Juli Switala

SPEAKER	TOPIC
Dr. Susan Purchase Desmond Tutu TB Centre	Impact of levofloxacin on non-TB clinical outcomes in young children receiving preventive treatment for multidrug-resistant TB.
Dr. Paulin Kayembe NIFDAR PBO	Paediatric TB care in West Rand District: high treatment initiation with persistent gaps in TB preventive therapy uptake.
Ms. Delly Mashele Institute of Health Programs and Systems	Improving TB preventive therapy (TPT) initiation among children under five through facility - and community-based social auxiliary worker (SAW) counselling.
Dr. Karen du Preez Stellenbosch University	From Symptoms to Survival: Strengthening the TB care cascade for children and adolescents.



10 June 2026

Track 4, Session 4: People-Centred TB Care: From guideline implementation to improved outcomes

Time: 16:00 – 17:30
Venue: Heathrow
Session Chair: Dr. Lee-Ann Davids
Session Co-Chair: Dr. Josephine Otchere-Darko

SPEAKER	TOPIC
Mr. Tseko Manzini Imbali YaManzi Foundation	The impact of TB on people with disabilities, in the West Rand District.
Mr. Zamani Dlamini Durban University of Technology	The practices of health care workers regarding the implementation of tb guidelines in king Cetshwayo district.
Mr. Goodman Makanda TB Proof	Feasibility and acceptability of a TB survivor-led peer support intervention using motivational interviewing to address TB/HIV intersectional stigma in South Africa.
Mr. Zamani Dlamini Durban University of Technology	Factors that influence the implementation of TB guidelines at King Cetshwayo district.
Dr. Lehlogonolo Makola Human Sciences Research Council	Intersections of TB- and HIV-related stigma among people living with HIV in South Africa: Insights from the 2024 Stigma Index 2.0.

Satellite Session

National Department of Health (NDoH), Republic of South Africa

Time: 16:00 – 17:30
Venue: Charles De Gaulle

DINNER BREAK (17:30 – 18:00)



11 June 2026

Plenary Speaker Biographies



His Excellency Paul Mashatile

Deputy President
Republic of South Africa

Mr Paul Mashatile is the Deputy President of the Republic of South Africa serving since March 2023 and is a senior leader of the African National Congress ANC. He has held a wide range of political and executive

roles across provincial and national government reflecting a long career in public service.

His previous positions include Gauteng MEC for Safety and Security MEC for Transport and Public Works and Premier of Gauteng from 2008 to 2009. At national level he has served as Minister of Arts and Culture and Minister of Human Settlements contributing to governance in cultural development and housing policy. Within the ANC he has also served as Treasurer-General playing a key role in party administration and financial oversight.

His current role as Deputy President involves supporting the President in coordinating government priorities driving service delivery and strengthening policy implementation across sectors across all levels of government today effectively.

(MBA). Dr Maimela is currently a member of the Dira Sengwe Board. She hosted the 10th SAAIDS virtual conference in 2020 and was nominated to chair the 11th SAAIDS conference in 2023. Dr Maimela is also a member of the Africa Telehealth Collaboration steering committee that seeks to address barriers to the expansion of telehealth in South Africa and the rest of the African region.



Mr. Solly Nduku

Deputy Chairperson
South African National AIDS Council

Mr. Solly Nduku is the Co-Chairperson of SANAC and National Chairperson of SANAC CSF, with extensive leadership and traditional health expertise. He serves

as General Secretary of NUPAATHPSA and has led the Traditional Health Practitioners sector in SANAC CSF since 2009. Previously the 1st Deputy Chairperson of SANAC CSF, he also co-chaired the Global Fund Country Coordinating Mechanism. His leadership includes provincial roles in NUPAATHPSA and service as a municipal councillor and MMC. In 2019, he represented traditional and allied health professionals in the Presidential Health Compact, signing on behalf of the sector with President Cyril Ramaphosa.



Dr. Gloria Maimela

Chief Executive Officer
Foundation for Professional
Development

Dr Gloria Maimela is a Medical Doctor with vast experience in HIV treatment and prevention programming and recently climate change and health. She holds

a Bachelor of Nursing degree, a Bachelor of Medicine and Surgery, a Diploma in HIV Management and a Master's in business administration



11 June 2026

Plenary Speaker Biographies



Prof. Khangelani Zuma

Divisional Executive, Human Sciences Research Council

Prof. Khangelani Zuma Divisional Executive of Human and Social Capabilities and head of biostatistics at the Human Sciences Research Council based in Pretoria. Prof Zuma has over 12 years of experience as a statistician. He has been involved in large scale surveys and clinical trials as a statistician focusing on conceptualisation, design and implementation of these studies.

His expertise and research interest span around survey design, complex data analyses, linear and non-linear mixed models, hierarchical Bayesian models, (correlated) survival data analyses, epidemiology: modelling infectious diseases data, HIV incidence estimation and monitoring and evaluation of HIV intervention programmes.

Prof. Zuma has also taught statistics at both undergraduate and postgraduate levels. His recent publications include authoring and co-authoring papers published in peer-reviewed journals in the areas of HIV/AIDS, sexually transmitted infections, migration and biostatistics. He has presented papers at both local and international conferences. He is currently the chair of the ministerial committee Health Data Advisory and Coordinating Committee and a member of the Statistics Council of Statistics South Africa.

Prof. Khangelani Zuma has been appointed as Honorary Associate Professor in the School of Public Health. The appointment is effective from 01 October 2018.



Dr. Tshepo Sedibe

Occupational Health Professional

Dr. Tshepo Sedibe is a South African medical and occupational health professional known for his leadership in workplace wellness, HIV/AIDS management, mental health advocacy, and employee health programmes in the mining sector.

Dr. Sedibe is especially recognised for helping drive De Beers' pioneering HIV/AIDS workplace programmes in Southern Africa. Under these initiatives, the company introduced free HIV testing, counselling, antiretroviral treatment,

and support programmes for employees and their families. Reports indicate these interventions significantly reduced AIDS-related mortality among employees and improved HIV treatment outcomes.

He is based in Johannesburg and has represented De Beers in national and regional health initiatives involving government, labour, and industry stakeholders.



Mr. Nare Komape

Nurse and Assistant Manager

Mr. Nare Komape is a professional nurse and Assistant Manager for communicable diseases at national level with the Department of Correctional Services, he plays a key role in communicable disease surveillance, prevention and control in correctional settings. His work includes policy development, strengthening infection prevention strategies and analysing epidemiological data to inform targeted interventions among high-risk populations.

He holds a diploma in nursing science, B Cur (ADM et Edu) Occ Health Nursing Science and diploma in Ophthalmology nursing science. Currently pursuing a Master in Public Health (Epidemiology and Biostatistics) at the University of Kwazulu-Natal. He is committed to advancing evidence based disease prevention. He also serves as Chairperson of the South African Society for Ophthalmic Nurse.



11 June 2026

Plenary Speaker Biographies



Dr. Thabo Mpotje

Senior Research Scientist

Dr. Thabo Mpotje is an immunologist and Senior Research Scientist with expertise in the pathophysiology and immunobiology of infectious diseases, with a particular focus on host immune responses that drive disease progression and tissue pathology. I

am currently affiliated with the Africa Health Research Institute (AHRI) in South Africa and hold a joint affiliation with the School of Life & Medical Sciences at University College London.

He obtained his PhD in Medicine, specialising in Clinical Sciences and Immunology, from the University of Cape Town, where he also completed his MSc in the same field. His research integrates cellular immunology, translational science, and experimental models to identify host factors that influence disease outcomes and to uncover novel targets for host-directed therapies.

His work has contributed to advancing the understanding of immune-mediated pathology in infectious diseases, including TB and schistosomiasis. I have authored over 17 peer-reviewed publications in internationally recognised journals such as EMBO Molecular Medicine, Mucosal Immunology, Frontiers in Immunology, and the Journal of Experimental Medicine. His research has been supported by competitive funding, including awards from the South African Medical Research Council (SAMRC), as well as support linked to Wellcome Trust and Bill & Melinda Gates Foundation initiatives.

In addition to his research, he is actively involved in postgraduate supervision and mentorship, having co-supervised MSc and PhD students and supported the development of emerging researchers. He contributes to teaching through guest lectures in advanced immunology and interdisciplinary programmes, and he serves the scientific community as a reviewer for funding bodies and international conferences.

His research vision centres on advancing host-directed therapeutic strategies and developing translational immunology platforms to address major health challenges in South Africa and globally, including infectious diseases, respiratory pathology.



Dr. Masindi Mashapha

Assistant Director

Dr Masindi Mashapha obtained a Doctoral degree in Public Affairs from Tshwane University of Technology in 2023. She received Kistefos scholarship twice to participate in the Implementing Public Policy and Arts and Practice of Leadership

courses at Harvard Kennedy School, Boston, Massachusetts, USA in 2022 and 2024 respectively.

She was nominated to participate during the 2nd BRICS Postgraduate Forum at Cape Town, South Africa in 2023 and the Fifth African women leadership programme at Cairo, Egypt in 2024. Dr Mashapha has just recently participated in the seminar on CDC construction and Public Health for African countries in Guangdong Guangzhou, in China from 20 May - 02 June 2026.

Currently, Dr Mashapha is the Assistant Director responsible for Coordination and Stakeholder Management at the HIV and AIDS Chief Directorate of the National Department of Social Development. Her passion in HIV and TB saw her coordinating the DSD TB programme. She is a published scholar who is also the External Writer for UNISA and a Supervisor of 3 Master's students at TUT.

Recently, Dr Mashapha has been appointed to serve in the Research committee of the Public Health and Social Development Sector Bargaining Council (PHSDSBC) and the professional designation committee of the South African Association of Public Administration and Management (SAAPAM).



11 June 2026

Plenary Session 4 : Sustaining TB and HIV Programs in the Era of Funding Volatility: Innovations, Adaptations, and Policy Insights for Future Epidemic Control

Time: 09:00 – 09:20
Venue: OR Tambo
Session Chair: Mr David Macana,
Dr Roger Philo

PRESENTER

Prof. Khangelani Zuma
Divisional Executive, Human Sciences Research Council

SANAC Round Table Discussion on Strengthening Multisectoral Accountability for TB in South Africa: From Legislative Oversight, Community Monitoring, Multisectoral Action to Measurable Action

Time: 09:20 – 10:00
Venue: OR Tambo
Session Chair: Dr. Nkhensani Nkhwashu

PRESENTER

Dr. Masindi Mashapha
Department of Social Development

Mr. Nare Komape
ASD Communicable Diseases, Directorate: Health Care Services, Department of Correctional Services

Mr. Solly Nduku
South African National AIDS Council

Dr. Tshepo Sedibe
South African National AIDS Council

Hon Dr Bandile Masuku

BREAK & NETWORKING (10:00-10:30)

Closing Plenary Session

Time: 10:30 – 12:30
Venue: OR Tambo
Session Chair: Prof. Mohlopheni Jackson Marakalala & Dr. Nkateko Mkhondo

PRESENTER

TOPIC

ENTERTAINMENT

Dr. Thabo Mpotje
Chief Rapporteur

Conference Rapporteur feedback

Awards

- Discovery: Best Oral and Best Poster
- MRC Amazing Race winner

Prof. Mohlopheni Jackson Marakalala
Conference Chair, South African Medical Research Council
&
Dr. Nkateko Mkhondo
Conference Co-Chair, Senior Public Health Specialist

Conference Overview

Dr. Gloria Maimela
Chief Executive Officer, Foundation for Professional Development

FPD Acknowledgement & Introduction to the 10th SA TB conference 2028

ENTERTAINMENT

His Excellency Paul Mashatile
Deputy President, Republic of South Africa

Keynote address

Dr. Gloria Maimela
Chief Executive Officer, Foundation for Professional Development

Vote of Thanks & Closing



Rapporteurs

<p>Dr. Thabo Mpotje Research Associate, Africa Health Research Institute</p>	Chief Rapporteur
<p>Dr. Farzana Ismail Pathologist, National Institute For Communicable Diseases</p> <p>Mrs. Deanne Goldberg TB Program Manager, Clinton Health Access Initiative, South Africa</p>	Track 1
<p>Dr. Nonzwakazi Ntombela Study Coordinator, CAPRISA</p> <p>Mrs. Nelly Jinga Researcher – Epidemiology, Health Economics and Epidemiology Research Office (HE2RO)</p>	Track 2
<p>Mr. Mthokozisi Dube Study Coordinator, Aurum Institute</p> <p>Mr. Sthabiso Bohlela Research Study Coordinator, Africa Health Research Institute</p> <p>Ms. Andani Ratshinga Project Coordinator, Africa Health Research Institute</p>	Track 3
<p>Ms. Sewele Dlamini Programme Manager, South African National AIDS Council</p> <p>Mr. James Mmekwa Programme Manager, South African National AIDS Council</p>	Track 4

Poster Moderators

TRACK 1

Mrs. Leisha Genade
Dr. Firdaus Nabeemeeah
Dr. Halima Said
Ms. Lavania Joseph
Ms. Carroll Tshabane

TRACK 2

Dr. Marian Loveday
Dr. Wasila Jassat

TRACK 3

Ms. Nontobeko Ndlovu
Ms. Tanyaradzwa Dube
Dr. Katlego Motlhaoleng
Mrs. Leisha Genade
Ms. Andani Ratshinanga
Ms. Nompumelelo Ngobese

TRACK 4

Dr. Mlungisi Ntshangase



Poster Presentations

Track 1: Basic/Translational and Clinical Sciences

Poster No.	Sub-Track	Name	Topic	Organisation
186	Clinical Epidemiology	Mr. Thato Nkwagatse	The prevalence and clinicopathological characteristics of Extra Pulmonary TB at Tertiary Laboratory in Northern Pretoria: A five-year retrospective study.	National Health Laboratory Service
132	Clinical Epidemiology, Science & Outcomes	Ms. Phindile Msomi	Severe skin reaction during TB treatment: a clinical case study.	Centre for the AIDS Programme of Research in South Africa
209	Clinical Microbiology	Dr. Ndivhuho Makhado	Non-tuberculous mycobacteria isolated at a tertiary laboratory, in South Africa, using the GenoType Mycobacterium CM/AS assay and 16S rRNA gene sequencing.	Africa Health Research Institute
216	Clinical Microbiology	Ms. Muthanyi	Investigating the Prevalence of Clinically Significant Non-Tuberculous Mycobacteria Species at a Tertiary Laboratory in Pretoria.	Sefako Makgatho Health Sciences University
286	Clinical Microbiology	Dr. Nina von Knorring	Non-tuberculous mycobacteria isolated from BACTEC™ blood cultures over a 10-year period at the Mycobacteriology Referral Laboratory, Johannesburg, South Africa.	National Health Laboratory Service
120	Clinical Outcomes	Dr. Mandisa Ngema	TB Mortality Among HIV Co-Infected Patients in Gauteng, South Africa: Insights from the Johannesburg and Sedibeng Districts.	Africa Health Research Institute
224	Clinical Science	Dr. Marguerite Hall	TB Still Kills: Evidence from Post-mortem Minimally Invasive Tissue Sampling.	University of the Witwatersrand – Vaccines and Infectious Diseases Analytics
215	Co-infections	Ms. Buhle Mahlangu	Investigation of TB and fungal co-infection in patient samples at a Tertiary Laboratory in Pretoria, South Africa.	Sefako Makgatho Health Sciences University
314	Co-infections	Dr. Ted Odede	Early Thrombocytosis and Transient Platelet Worsening Following Initiation of Treatment for Pulmonary TB.	Enhancing Care Foundation
99	Diagnostics & Biomarkers	Dr. Munyaradzi Musvosvi	Evaluation of capillary blood as a sample source for measuring M.tb-specific T cell responses.	University of Cape Town, South African TB Vaccine Initiative
114	Diagnostics & Biomarkers	Ms. Mmule Mathebe	Diagnostic performance of the FluoroType MTBDR Assay for Rifampicin and Isoniazid Resistance in Routine Laboratory Setting.	University of Limpopo
117	Diagnostics & Biomarkers	Mr. Mahlatshe Maseeme	Biomarkers for asymptomatic TB (TB).	Africa Health Research Institute
149	Diagnostics & Biomarkers	Mr. Carl Baumeister	Internal diagnostic validation of electro-impedimetric detection of blood anti-mycolate antibodies in presumptive TB patients.	Microprocessor And Radio Telephone Interconnection
273	Diagnostics & Biomarkers	Ms. Thabiso Seiphetlo	Urine LAM as a potential non-invasive biomarker for TB treatment monitoring.	Perinatal HIV Research Unit
298	Diagnostics & Biomarkers	Ms. Mamello Motsei	Determining the limit of detection for rapid Determine TB LAM antigen test using standardised Mycobacterium TB culture dilutions.	National Institute for Communicable Diseases
340	Diagnostics & Biomarkers	Dr. Farzana Ismail	Evaluation of the Standard-Q TB MPT64 Antigen test for the detection of Mycobacterium TB complex.	National Institute for Communicable Diseases
91	Diagnostics Innovation	Mr. Kabelo Kaapu	Genomic variants and associated drug resistance profiles revealed by whole genome sequencing in drug resistant M. TB clinical isolates from Limpopo province.	University of Limpopo
161	Diagnostics Innovation	Dr. Ditshego Ralefeta	Non-Culture-Based Classification of Mycobacterium TB and Clinically Relevant Bacteria Using Raman Spectroscopy.	University of Cape Town
299	Diagnostics Innovation	Ms. Mamello Motsei	Pilot Evaluation of an Instrument-Free and cost-efficient Mycobacterium TB DNA Extraction method for downstream Molecular Diagnostics.	National Institute for Communicable Diseases



Poster Presentations

Track 1: Basic/Translational and Clinical Sciences

153	Drug Discovery	Mr. Llewellyn Oswald Buys	Repurposing piroxicam as an antimicrobial drug against Mycobacterium TB.	Stellenbosch University
159	Drug Discovery	Ms. Tamia Lawrence	Boosting Immunity: Screening Immunomodulators for Enhanced Antimicrobial Therapy in TB.	South African Medical Research Council
192	Drug Discovery	Dr. Itumeleng Setsshedi	Toward Novel Antitubercular Agents: In Silico Evaluation of Isoniazid Analogues as Potential Catalase–Peroxidase (KatG) Inhibitors.	University of South Africa
248	Drug Discovery	Ms. Maphuti Matlala	Antimycobacterial potential of traditionally used medicinal plants and their impact on mycobacterial protein expression.	University of Limpopo
256	Drug Discovery	Ms. Lethabo Mashilo	Evaluation of phytochemicals, antioxidant, antimycobacterial and anti-virulence activity of selected medicinal plants used for treatment of TB and related symptoms .	University of Limpopo
185	Drug Resistance	Dr. Awelani Mutshembele	Hidden Isoniazid Resistance and Widespread Rifampicin Heteroresistance: Implications for TB Control in South Africa.	South African Medical Research Council
187	Drug Resistance	Ms. Senamile Ngema	Minimum Inhibitory Concentrations Distributions and Genotypic Profiles of Bedaquiline-Resistant Mycobacterium TB Clinical Isolates.	Centre for the AIDS Programme of Research in South Africa
302	Drug Resistance	Mr. Dumsani Ngcamu	Pretomanid minimum inhibitory concentration (MIC) distributions in South African Mycobacterium TB clinical isolates: A 5-year resistance surveillance program.	National Health Laboratory Service
348	Drug Resistance	Dr. Santhuri Rambaran	Phenotypic drug resistance profiles among patients receiving Extended Drug Resistance testing not responding to a drug resistant TB regimen in South Africa.	National Institute for Communicable Diseases
131	Host–Pathogen Interaction	Dr. Naomi Okugbeni	Application of a Physiological Autophagy Assay to Quantify Host Mycobactericidal Capacity.	South African Medical Research Council
135	Host–Pathogen Interaction	Ms. Leegan Govender	Whole-Blood Autophagy Flux Measurement in TB: A Pilot Study.	South African Medical Research Council
227	Host–Pathogen Interaction	Dr. Thabo Mpotje	Associations Between Diverse Macrophage Subsets and Pathological Drivers of Lung Damage in TB.	Africa Health Research Institute
265	Host–Pathogen Interaction	Mrs. Anika Chicken	Reduced Short-Chain Fatty Acid-Producing Capacity of the Gut Microbiome During Rifampicin-Resistant and Multidrug-Resistant TB Treatment.	Stellenbosch University
323	Lab Quality & Systems	Ms. Yasmin Gardee	National Verification of the commercial research use only Bedaquiline drug kit by Becton Dickinson (BD).	National Institute for Communicable Diseases
103	Molecular Biology & Genomics	Ms. Noxolo Ntuli	The effect of long non-coding RNA 810 on macrophages during Mycobacterium TB infection.	University of Cape Town
151	Molecular Biology & Genomics	Mrs. Maborwa Matjokotja	Role of the Trk potassium-uptake transporter and the KdpDE regulatory system in biofilm formation of Mycobacterium TB.	University of Pretoria
152	Molecular Biology & Genomics	Dr. Nontuthuko Maningi	Application of CRISPR/Cas9 to Validate the Functional Role of pncA Gene Mutations in Mycobacterium TB.	University of Kwazulu-Natal
228	Molecular Biology & Genomics	Ms. Asanda Nyide	Lineage-specific non-coding RNA regulatory networks in the Mycobacterium TB complex.	University of Kwazulu-Natal
258	Molecular Biology & Genomics	Ms. Kiara Ramchunder	Functional characterization of novel mycobacterial zinc metalloprotease MSMEG3019 and its role in bacterial physiology.	University of Kwazulu-Natal
257	Molecular Epidemiology	Ms. Rabelani Mafunise	Genetic Diversity and Drug Resistance Profiles of Mycobacterium TB Isolates in a Tertiary Laboratory.	Africa Health Research Institute
238	Population Impact	Mr. Mohau Khobedi	TB: Impact on Young Children and Youth.	Are Aganeng
150	Programme Outcomes	Mr. Lungani Ndwandwe	Title: Declining Drug-Susceptible TB Lost to Follow-Up Rates in King Cetshwayo District Municipality in South Africa.	Isibani



Poster Presentations

Track 1: Basic/Translational and Clinical Sciences

184	Risk Factors	A/Prof. Denise Evans	Alcohol Use and Disease Severity in TB: Results from a multi-country cohort analysis.	University of the Witwatersrand
361	Diagnostics Innovation	Dr. Galina Bogoslovskaya	Successful Management of Life-Threatening Tuberculous Cardiac Tamponade in the Postpartum Period: A Case Report.	Pietersburg Provincial Hospital
362	Treatment Outcomes	Ms Thabiso Mphephu	Tuberculosis in vivo drug efficacy testing platform at the University of Cape Town.	University of Cape Town



Poster Presentations

Track 2 – Prevention, TB Vaccines, treatment strategies; including clinical trials; drug testing, lab to biotech partnerships

Poster No.	Sub-Track	Name	Topic	Organisation
109	Behavioural Science & Demand Creation	Mr. Mabalane Mfundisi	Leveraging social media for targeted health mobilization among key populations: Programme lessons from a community-led digital outreach initiative.	United Nations Programme on HIV/AIDS (UNAIDS)
296	Behavioural Science & Demand Creation	Dr. Lindiwe Tsope	Perceptions of universal TB testing among persons with TB and household contacts in Lesotho, South Africa and Tanzania.	Aurum Institute
108	Case Finding & Prevention Therapy	Mr. Thapelo Mokone	Community-led active case finding and adherence support to reduce TB treatment defaulting among men in Merafong City: Implementation lessons from Khutsong South.	Civil Society Forum
242	Case Finding & Prevention Therapy	Mr. Tionge Sikwese	Uptake and Completion of TB Preventive Therapy in Populations Beyond Household Contacts and People Living with HIV: A Systematic Review and Meta-Analysis.	Kamuzu
324	Diagnostics & Innovation	Mr. Albert Maribe	Impact of National Health Laboratory Service Cyber-Attack on TB Testing, 2024.	National Institute for Communicable Diseases
175	Drug Discovery & Translational Science	Mr. Funi Thagulisi	Bioprospecting intertidal sediment-derived bacteria for novel antimycobacterial agents.	Stellenbosch University
235	Drug Discovery & Translational Science	Dr. Ibrahim Tukur	A cyclomarin-based BacPROTAC strategy to degrade DnaK as a novel therapeutic approach against Mycobacterium TB.	Stellenbosch University
28	Epidemiology & Risk Factors	Mr. Niringiyimana Benjamin	Closing the missing millions: impact of integrated community active case finding on tb detection in high-burden districts of Uganda	Supranational Reference Laboratory Uganda
338	Epidemiology & Risk Factors	Ms. Keatlegile Moatshe	Factors associated with self-reported TB morbidity among youth in South Africa.	North-West University
355	Epidemiology & Risk Factors	Mr. Katlego Motlhaoloa	MDR-TB and HIV/Aids Co-Infection Rates in the Free State Province: Impact on Treatment Outcomes.	Department of Health
46	Epidemiology & Risk Factors	Ms. Nontobeko Ndlovu	Impact of viral load non-suppression on drug-resistant TB outcomes among people living with HIV: Scoping review.	Aurum Institute
85	Epidemiology & Risk Factors	Ms. Pelokazi Siyengu	Genomic Characterization and Evolution of Drug-Resistant Mycobacterium TB in Patients with Persistent Culture Positivity in the Western Cape, South Africa, 2019–2023	Stellenbosch University
10	Integrated Care & Systems	Mr Gcina Sawuka	Optimizing Advanced TB Management for Sustainable TB-Free Generation through Enhanced Treatment, Prevention and Diagnostics Tools.	Treatment Optimization Campaign
31	Integrated Care & Systems	Mr. Tsietsi Mtholo	Addressing the High TB Burden in Gauteng through Integrated HIV and TB Services	Gauteng Aids Council
33	Integrated Care & Systems	Mr. Tsietsi Mtholo	Integrating Mental Health into HIV and TB Services: A New Frontier in Gauteng's Provincial Implementation Plan.	Gauteng AIDS Council
346	Integrated Care & Systems	Ms. Catherine Ntshane	Strengthening TB research through Health-System Partnership: Practice-Based Insights from Tshwane District, South Africa.	Setshaba
78	Key Populations & Equity	Dr. Ndumiso Tshuma	Reaching men where they work: A human-centered, community-embedded HIV service delivery model for mining communities in Jos Plateau, Nigeria.	Best Health
95	Key Populations & Equity	Ms. Ntombi Xolani	Addressing the crisis of Inequity; Inadequate public healthcare for TB amongst South African Girls.	Independent
240	Key Populations & Equity	Dr. Phindile Shangase	The role of persons with disabilities in TB prevention.	University of Free State
357	Key Populations & Equity	Ms. Martina Motaung	Understanding and addressing TB's risk, care barriers and stigma in LGBTQI communities in SA: A community engaged mixed methods study.	Meisie Motaung Foundation
26	Key Populations & Equity	Mr. Gcina Sawuka	Unlocking TB Elimination: Optimizing Mining Sector Interventions in South Africa" Addressing TB burden in mining communities through enhanced case finding, treatment, and prevention strategies.	Treatment Optimization Campaign
90	Prevention & Community Interventions	Mr. Siphelele Dhlamini	Harnessing Sports, Arts, and Culture to Enhance TB Awareness Among Men in Urban South Africa: Insights from Community-Driven Approaches	Isibani



Poster Presentations

Track 2 – Prevention, TB Vaccines, treatment strategies; including clinical trials; drug testing, lab to biotech partnerships

104	Prevention & Community Interventions	Mr. Siphamandla Mpungose	Breaking the Silence: Community-Led TB Awareness, Screening Demand Creation and Referral Pathways through Civil Society Engagement in South Africa.	Isibani
213	Prevention & Community Interventions	Dr. Bhekani Buthelezi	"TB Is Curable": Exploring the Role of Music in Promoting Curability Awareness at the Grassroots Level.	Unizulu
253	Prevention & Community Interventions	Mr. Velaphi Mazomba	Using Community Soccer Tournaments to Promote TB Awareness and Youth Engagement in Township Communities.	Ngaphandle
17	Prevention & Community Interventions	Mr. Gcina Sawuka	Reimagining Community Health: Strengthening Integrated Optimal TB Response.	Treatment Optimization Campaign
32	Treatment Strategies & Outcomes	Mr. Tsietsi Mtholo	Improving TB Treatment Outcomes in Gauteng: Responding to High Loss to Follow-Up and Mortality.	Gauteng Aids Council
49	Treatment Strategies & Outcomes	Ms. Gcinile Dlamini	Persistent Culture Positivity and Community Exposure: Programmatic and Ethical Challenges in Managing Bedaquiline-Resistant MDR-TB.	Baylor
193	Treatment Strategies & Outcomes	Dr. Mei Hi Lee	Achieving an 88% completion rate in treatment of latent TB infection: impact of case management and short-course regimens in Northern Taiwan.	Taipei Medical
233	Treatment Strategies & Outcomes	Mr. Mlungisi Nkambule	Implementation of Video-observed therapy under the programmatic condition for DR-TB / HIV patients: A lesson learnt from Eswatini.	AIDS Healthcare Foundation
234	Treatment Strategies & Outcomes	Mr. Mlungisi Nkambule	Lessons Learnt from MDR- Tb/HIV Patients Receiving Comprehensive Patient Supporting Eswatini.	AIDS Healthcare Foundation
38	Vaccines & Clinical Trials	Mr. John Mdluli	Enhancing the acceptability of a phase three TB vaccine trial in the Matlosana subdistrict.	Aurum Institute
334	Vaccines & Clinical Trials	Dr. Priashni Subrayen	From Breakthrough to Rollout: Preparing South Africa for a Transformative TB Vaccine	Aurum Institute
359	Vaccines & Clinical Trials	Ms. Octavia Magopane	Integrated clinical research center selection for late-stage TB vaccine trials: The MTBVAC IMAGINE example.	International AIDS Vaccine Initiative
260	Health Systems Shock Responses	Mr. Kabelo Kaapu	Characterizing Bedaquiline, Pretomanid, and Linezolid Minimum Inhibitory Concentrations in a Rifampicin-Resistant TB Cohort: Insights from Limpopo Province	University of Limpopo



Poster Presentations

Track 3 – Advances in Epidemiology and Health Systems

Poster No.	Sub-Track	Name	Topic	Organisation
69	Adolescents & Youth Prevention	Dr. Ramneek Ahluwalia	Strengthening male psychosocial health and gender norm transformation in TVET colleges: Lessons from a hybrid peer-led and digital programme in South Africa.	Best Health Solutions
72	Adolescents & Youth Prevention	Ms. Nonhlanhla Khumalo	Implementing the My Journey programme: An integrated, Human-Centred model for adolescent and young people HIV and SRH service delivery in high-burden districts of Mpumalanga, South Africa.	Best Health Solutions
182	Children Diagnosis	Mrs. Portia Seatlholo	TB in children (0-14 years) in a Gauteng township: a descriptive study.	Foundation for Professional Development
70	Community, Behavioural & Social Determinants	Ms. Thandi Maluka	The hidden price of stigma: Health system and economic consequences of HIV-related discrimination in South Africa.	Best Health Solutions
75	Community, Behavioural & Social Determinants	Mr. Clinton Moyo	Integrating behavioural insights into the LEARN rollout: Community awareness, testing, and adoption through hybrid face-to-face and chatbot channels in Ethiopia.	Best Health Solutions
79	Community, Behavioural & Social Determinants	Ms. Thembi Nkomo	Sentiment analysis of social media reactions to TB survivor testimonies: Understanding public perceptions and engagement.	Best Health Solutions
80	Community, Behavioural & Social Determinants	Mr. David Macana	Using music and digital media to enhance TB awareness, reduce stigma and promote health-seeking behaviour among South African youth: A qualitative study.	Best Health Solutions
122	Community, Behavioural & Social Determinants	Ms. Thembi Nkomo	Exploring public sentiment and misinformation trends in TB awareness: A cross-platform social media analysis.	Best Health Solutions
124	Community, Behavioural & Social Determinants	Mr. Sipehelele Dlamini	From song to social action: Community-led TB case finding inspired by the End TB music campaign in South Africa.	Best Health Solutions
205	Community, Behavioural & Social Determinants	Ms. Monica Longwe	Strengthening the Foundations: Building National SBCC Capacity to Implement the End TB Campaign in South Africa.	Department of Health
44	Community, Behavioural & Social Determinants	Mrs. Caroline Tiba	Community-based HIV/TB testing, ART initiation, and prevention services in the West Rand, South Africa: Outcomes from Rotanganedza Community Care.	Rotanganedza Community Care
59	Community, Behavioural & Social Determinants	Ms. Lindiwe Mahlangu	Enhancing TB Prevention and Control Strategies at Health Facilities: A Holistic Approach.	Positive Women's Network
137	Cross-cutting Data Systems	Mr. Lubabalo Mangoloti	Strengthening Data Quality to Improve BPAL-L Treatment Outcomes.	Department of Health
181	Cross-cutting Data Systems	Dr. Hanlie Myburgh	Fit for purpose? Assessment of drug-susceptible TB data systems and programme needs in three South African provinces.	Drug-Target Therapeutics and Chemical Biology
306	Cross-cutting Data Systems	Ms. Sinothando Dlamini	Evaluation of the TB Module on the Notifiable Medical Conditions Platform, South Africa, Gauteng Province, 2022 - 2023.	National Institute for Communicable Diseases
310	Cross-cutting Data Systems	Mr. Ayanda Shabalala	Public Facing EndTB Campaign Dashboard in South Africa, 2025-2026.	National Institute for Communicable Diseases
116	Diagnosis Pathways	Dr. Lindokuhle Dlamini	The role of demographic disparities delaying TB (TB) diagnosis among rural population in Eswatini: a target for innovative screening interventions.	National TB Programme
194	Diagnosis Pathways	Prof. Alison Grant	Detection of drug resistance by BD MAX MDR-TB vs. Xpert MTB/RIF Ultra in a programmatic setting in South Africa.	London School of Hygiene & Tropical Medicine
198	Diagnosis Pathways	Ms. Patience Baloyi	Caregivers' experiences during their child's journey to TB diagnosis and treatment.	Stellenbosch University
270	Diagnosis Pathways	Dr. Robina Semphere	Patterns of health facility access for TB care among patients in Blantyre Malawi: an epidemiological analysis.	Kamuzu University of Health Sciences
271	Diagnosis Pathways	Dr. Robina Semphere	Navigating Uncertainty: Pre-Diagnostic TB Experiences and Care-Seeking in Urban Malawi.	Kamuzu University of Health Sciences
250	Diagnosis Pathways	Dr. Firdaus Nabeemeeah	Biomarkers for diabetes mellitus (DM) and inflammation in people diagnosed with pulmonary TB (PTB).	Perinatal HIV Research Unit



Poster Presentations

Track 3 – Advances in Epidemiology and Health Systems

110	Digital Innovation	Mr. Tshepo Ndhlovu	Empowering community-based organizations through gamification: Enhancing Monitoring & Evaluation capacity in Gauteng, South Africa.	Best Health Solutions
139	Digital Innovation	Ms. Libertina Shiweva	Integrating Agile Project Management into The Implementation of Enhanced Case Finding For Drug-Resistant: Preliminary Results from The H3TB Project In Namibia.	University of Namibia
283	Digital Innovation	Mr. Raj Govender	Strengthening TB Programme and System Implementation Through Standardised, Video-Based Training Approaches.	Consultant
293	Digital Innovation	Mr. Raj Govender	Strengthening Community-Based TB Service Delivery through Aligned Low-Cost, Open-Source Digital Monitoring and Evaluation (M&E) Systems .	Consultant
71	Digital Innovation	Prof. Martha Chadyiwa	Translating human-centred acceptability evidence into a scalable WhatsApp-based digital health system in urban South Africa.	Best Health Solutions
76	Digital Innovation	Mr. Clinton Moyo	Embedding Human-Centred Behavioural Science to transform health ecosystems for adolescent girls and young women in Kenya.	Best Health Solutions
14	Epidemiology & Burden Cross-cutting	Mr. Gcina Sawuka	Advances in TB Epidemiology and Health Systems: Accelerating Progress towards TB Elimination.	Treatment Optimization Campaign
311	Epidemiology & Burden Cross-cutting	Dr. Lee-ann Davids	Epidemiological trends in Rifampicin-resistant TB burden across South Africa.	South African Medical Research Council
96	Epidemiology & Burden Diagnosis	Ms. Bernice Sekhonyana	Shifting Patterns of Bacteriologically Confirmed and Clinically Diagnosed TB in West Rand District, South Africa: Implications for Diagnostic Strengthening.	West Rand Health District
115	Epidemiology & Burden Diagnosis	Mr. Sthabiso Bohlela	Baseline characteristics and Mycobacterium TB bacillary burden among people living with HIV and HIV-negative adults starting TB treatment: uMkhanyakude district, South Africa	Africa Health Research Institute
344	Epidemiology & Burden Transmission	Ms. Kegaugetswe Motsomi	Spatial Distribution of Xpert MTB/RIF Ultra Cycle Threshold Values and Mycobacterium TB Transmission in a High-Burden TB Setting.	Centre for the AIDS Programme of Research in South Africa
176	Health Systems	Mr. Khumo Modiba	The cost of BPAL/L for multi-drug resistant TB treatment in South Africa: primary health care and hospital estimates.	Health Economics and Epidemiology Research Office
23	Health Systems Contact Investigation	Mr. Acheampong Kudom	TB Contact Investigation in High-Burden Settings: Data Quality, Health System Constraints, and Patient Disclosure of Contacts, Evidence from Ghana.	Methodist Medical Center-Bebu Ghana
19	Health Systems Environment	Ms. Rosina Moroane	Mitigating TB Risk in the West Rand: Nature-Based Dust Suppression and Carbon Sequestration on Mine Tailings to Improve Community Respiratory Health.	Ros40
337	Health Systems Innovation	Dr. Mmamapudi Kubjane	Projected health, budget, and cost-effectiveness impacts of stakeholder-informed TB vaccine delivery strategies in South Africa.	Health Economics and Epidemiology Research Office
65	Health Systems Integration	Dr. Logandran Naidoo	Observations from a nutritional support programme for clients with TB and HIV in selected South African clinics: The Food for Health programme.	AIDS Healthcare Foundation
168	Health Systems IPC	Mr. Dumisani Madhlophe	Improving Air Ventilation in Public Transport to Curb TB and Influenza Spread.	Sungulo
140	Health Systems Quality	Mr. Kavish Maharaj	Reducing South Africa's National Sputum Rejection Rate.	Genesis
143	Health Systems Quality	Mrs. Sebenzile Tuswa	Prognostic value of TUTT among HIV-positive patients in Randburg Clinic: weight changes as a surrogate marker for treatment response.	City of Johannesburg
241	Health Systems Shock Responses	Mrs. Nolundi Mshweshwe	Assessing the Impact of Flooding on TB Healthcare Delivery: A Case Study from the Eastern Cape Province, South Africa.	Aurum Institute
172	Household Contacts Prevention	Mr. Dawie Olivier	Perceived Social Support and Timely Clinic Presentation for Testing Among Household Contacts of TB Patients: A Cohort Study in Eastern Cape, South Africa.	Desmond Tutu Health Foundation
87	Maternal Health Access	A/Prof. Seani Mulondo	Barriers to accessing antenatal care services by pregnant women diagnosed with TB in Limpopo Province.	University of Venda
60	Men & Gender	Dr. Andre Swanepoel	Closing the TB gender gap in South Africa: operational priorities for improving detection and retention among men	University of Cape Town



Poster Presentations

Track 3 – Advances in Epidemiology and Health Systems

130	Screening & Case Finding	Ms. Mudzunga Neluheni	Strengthening TB Case Detection through Index Contact Tracing: A Comparative Analysis of Facility-based Contact Testing and TB Support Officer (TSO)- led Community-Based Contact Management in the Johannesburg Health District.	Institute of Health Programs and Systems (IHPS)
174	Screening & Case Finding	Mr. Lundi Ncana	Public/Private Partnership (PPM) – "A Much-needed intervention in Finding TB missing cases in the OR Tambo District, Eastern Cape".	Aquity
307	Screening & Case Finding	Ms. Funiwe Mkele	Clinic Referral Cards Contact Tracing Investigations for TB Screening – A TUTTPlus Study.	Perinatal HIV Research Unit
312	Screening & Case Finding	Dr. Edwin Klinkenberg	Performance of CAD4LungF for Identification of Lung Function Impairment From Chest X-Rays in TB Screening Programs in South Africa.	Delft Imaging
341	Screening & Case Finding	Mr. Wandile Vilakazi	Asymptomatic TB Prevalence in Integrated Lung Health Screening: Implications for De-stigmatization and Systematic Screening Policies.	Aquity
128	Screening & Case Finding	Ms. Caroline Tiba	Trends in TB screening, molecular testing, and treatment outcomes in the West Rand District, South Africa: A facility-based quantitative analysis.	Rotanganedza Community Care
86	Treatment, Adherence & Outcomes	Ms. Lelethu Bottoman	Exploring factors associated with completion of TB treatment in Buffalo City Metropolitan Health District, Eastern Cape Province, South Africa.	Department of Health
232	Treatment, Adherence & Outcomes	Dr. Nonzwakazi Ntombela	Clinical and behavioural predictors of delayed sputum culture conversion among TB patients with recurrent TB.	Centre for the AIDS Programme of Research in South Africa
252	Treatment, Adherence & Outcomes	Ms. Nobom Nini	Addressing TB Defaulter Rates and Late Presentation in a Clinic –Scarce communityNurse –Led and NPO–Supported model in Reeston ,Buffalo City Metro.	Siphethubomi
275	Treatment, Adherence & Outcomes	Mr. Master Modipane	Comparing of BPAL-L and 9-11 months regimen on treatment outcomes among patients with multidrug-resistant TB (DR-TB) in Ehlanzeni.	Aquity
352	Treatment, Adherence & Outcomes	Mr. Leole Setlhare	"Pre-XDR TB client benefiting from the unlikely situation of pregnancy: A Case report"	Department of Health
300	Treatment, Adherence & Outcomes	Mr. Makgalane Ramontsha	Associations Between TB, Multimorbidity, and In-Hospital Mortality Among COVID-19 Patients.	Human Sciences Research Council
358	Treatment, Adherence & Outcomes	Dr. Bongile Mabilane	High prevalence of asymptomatic TB in an African cohort of people with HIV (COVFN 3008 tb substudy).	University of Washington, Seattle, USA
93	Treatment, Adherence & Outcomes	Ms. Bulele Mokgatthe	High TB treatment initiation but sub-optimal treatment success: lessons from routine programme data in West Rand District, South Africa.	West Rand Health District



Poster Presentations

Track 4 – Sustainability in light of prevailing funding shortages

Poster No.	Sub-Track	Name	Topic	Organisation
18	Advocacy & Lived Experience	Mr. Obakeng Thiipe	Integrating Legal Literacy and TB Advocacy to Dismantle Structural Barriers in Mogale City.	New Start Youth
34	Financing & Sustainability	Mr. Tsietsi Motholo	Strengthening Governance and Sustainability of TB Control Programmes in Gauteng Province.	Gauteng AIDS Council
35	Financing & Sustainability	Mr. Tsietsi Motholo	Financing TB Control and Managing Donor Transition for Key Populations in Gauteng Province.	Gauteng AIDS Council
36	Innovation & Sustainability	Ms. Mpho Nathane	Using Natural Ventilation as a Climate-Smart Community Intervention for TB Prevention among Children and Adolescents.	Civil Society Forum
52	Priority Populations	Ms. Tshepelang Mlambo	Homeless People and TB spread.	Faith Home
53	Priority Populations	Mr. Siphon Dlamini	The impact of HIV, TB and STI's amongst the LGBTIQ+ Community MSM and SWW as a systematic barrier to healthcare Westrand District, Gauteng.	West Rand Youth Dev
55	Mental Health & Social Determinants	Ms. Nompumelelo Dube	A Retrospective Review of Mental Health Documentation and TB Treatment Outcomes in Ekurhuleni, Gauteng (Q1 2024).	Department of Health
56	Priority Populations	Mr. Sbusiso Biza	Examine stigma and discrimination amongst the LGBTQ+ community accessing healthcare services in the West Rand District, Gauteng.	Lisoletu Outreach
61	Mental Health & Social Determinants	Ms. Mabel Kenosi	The Silent Co-Epidemic: TB Risk and Mental Health Challenges in Adolescents and Youth.	Honey Guide
123	Financing & Sustainability	Mr. Tshepo Setlhabe	Sustainability, considering prevailing funding shortages.	Klerksdorp Tshepong Hospital
133	Social Support & Adherence	Ms. Livhuwani Mukondeleli	Improving Treatment Outcomes among Drug-Resistant TB (DR-TB) Patients through Social Auxiliary Worker (SAW)-Led Adherence Counselling in Johannesburg (JHB) Health District, South Africa.	Institute of Health Programs and Systems (IHPS)
146	Research & Trends	Dr. Tshiwela Neluheni-Tshinaba	Declining Drug-Resistant TB Case Detection associated with Improved Treatment Outcomes Following Implementation of the Short All-Oral BPAL-L Regimen in Johannesburg Health District and DR KK District, South Africa	Institute of Health Programs and Systems (IHPS)
156	Priority Populations	Ms. Khumo Molebatsi	Hidden in plain Sight TB Risk in children of informal Settlements	The Journey
158	Community-led & Civil Society	Mr. Lucky Mbillini	Breaking the silence and uniting for change community-based response to TB, and among women in Mogale City, West Rand District.	Lisoletu Outreach
169	Youth & Future Workforce	Ms. Zani De Wit	A CAB-led structured youth engagement model to strengthen sustainable TB research engagement at site level.	TB Alliance
189	Community-led & Civil Society	Ms. Buyisiwe Sibeko	Community-Driven Approaches to Strengthening TB Care Under Funding Constraints.	Sungulo Community Org
196	Mental Health & Social Determinants	Dr. Aaron Kipp	Socioeconomic Status Profiles Using Household Indicators in Eastern Cape: A Latent Class Analysis.	Brody School of Medicine, ECU
237	Community-led & Civil Society	Mr. Thapelo Mookwa	Community-Led Monitoring as a Sustainable, Rights-Based Approach to Strengthening TB Services in the Northern Cape.	Bathopele NGO
245	Research & Trends	Dr. Susan Purchase	Experiences of disseminating results from a community-based TB prevention trial in children in South Africa.	Desmond Tutu TB Centre
261	Advocacy & Lived Experience	Ms. Hannie Stevenson	#Vuka! Rising From Survival to Solidarity: A Lived-Experience Call to Unite Towards a TB-Free World.	Living With Hope
282	Innovation & Sustainability	Dr. Chihurumnanya Alo	Patent Vendors Involvement in the Treatment and Referral of Presumptive TB Cases in Abakaliki Metropolis, Ebonyi State, Southeast Nigeria.	AEFUTHA
330	Youth & Future Workforce	Mr. Kelvin Vollenhoven	Igniting the Future: Youth in STEM and Biomedical Research in the Cape Winelands District.	University of Cape Town
332	Nutrition & Support	Dr. Nirupa Misra	Collaborative Practices to Provide Nutritional Support to Vulnerable People with TB.	King Dinuzulu Hospital
335	Gender & Engagement	Ms. Mpho Nathane	Breaking barriers: Enhancing men's participation in TB programs.	Civil Society Forum

WUJKA

#SATBConference2026

Email: events@foundation.co.za | Phone: +27 12 110 4080